167 related articles for article (PubMed ID: 33173341)
1. Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer.
Ni J; Wang Y; Cheng X; Teng F; Wang C; Han S; Chen X; Guo W
Cancer Manag Res; 2020; 12():11085-11093. PubMed ID: 33173341
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Somatic
Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
[TBL] [Abstract][Full Text] [Related]
3. Identification of Somatic Mitochondrial DNA Mutations, Heteroplasmy, and Increased Levels of Catenanes in Tumor Specimens Obtained from Three Endometrial Cancer Patients.
Young MJ; Sachidanandam R; Hales DB; Brard L; Robinson K; Rahman MM; Khadka P; Groesch K; Young CKJ
Life (Basel); 2022 Apr; 12(4):. PubMed ID: 35455053
[TBL] [Abstract][Full Text] [Related]
4. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
5. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
6. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
7. mitoSomatic: a tool for accurate identification of mitochondrial DNA somatic mutations without paired controls.
Guo W; Liu Y; Su L; Guo S; Xie F; Ji X; Zhou K; Guo X; Gu X; Xing J
Mol Oncol; 2023 May; 17(5):857-871. PubMed ID: 36330809
[TBL] [Abstract][Full Text] [Related]
8. NGS-based profiling reveals a critical contributing role of somatic D-loop mtDNA mutations in HBV-related hepatocarcinogenesis.
Yin C; Li DY; Guo X; Cao HY; Chen YB; Zhou F; Ge NJ; Liu Y; Guo SS; Zhao Z; Yang HS; Xing JL
Ann Oncol; 2019 Jun; 30(6):953-962. PubMed ID: 30887045
[TBL] [Abstract][Full Text] [Related]
9. Oocyte mitochondrial deletions and heteroplasmy in a bovine model of ageing and ovarian stimulation.
Hammond ER; Green MP; Shelling AN; Berg MC; Peek JC; Cree LM
Mol Hum Reprod; 2016 Apr; 22(4):261-71. PubMed ID: 26792869
[TBL] [Abstract][Full Text] [Related]
10. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J
Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857
[TBL] [Abstract][Full Text] [Related]
11. Validation of Next-Generation Sequencing of Entire Mitochondrial Genomes and the Diversity of Mitochondrial DNA Mutations in Oral Squamous Cell Carcinoma.
Kloss-Brandstätter A; Weissensteiner H; Erhart G; Schäfer G; Forer L; Schönherr S; Pacher D; Seifarth C; Stöckl A; Fendt L; Sottsas I; Klocker H; Huck CW; Rasse M; Kronenberg F; Kloss FR
PLoS One; 2015; 10(8):e0135643. PubMed ID: 26262956
[TBL] [Abstract][Full Text] [Related]
12. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
13. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.
Ni MW; Zhou J; Zhang YL; Zhou GM; Zhang SJ; Feng JG; Xu Q; Zhou Y; Mou HZ; Zheng ZG
Biomark Med; 2019 May; 13(7):535-543. PubMed ID: 31140829
[No Abstract] [Full Text] [Related]
15. Multi-regional sequencing reveals intratumor heterogeneity and positive selection of somatic mtDNA mutations in hepatocellular carcinoma and colorectal cancer.
Li X; Guo X; Li D; Du X; Yin C; Chen C; Fang W; Bian Z; Zhang J; Li B; Yang H; Xing J
Int J Cancer; 2018 Sep; 143(5):1143-1152. PubMed ID: 29569724
[TBL] [Abstract][Full Text] [Related]
16. Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
Li Y; Zhang X; Gao Y; Shang C; Yu B; Wang T; Su J; Huang C; Wu Y; Guo H; Ha C
Front Oncol; 2020; 10():625866. PubMed ID: 33747898
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan RD; Clamp AR; Evans DGR; Edmondson RJ; Jayson GC
Cancer Chemother Pharmacol; 2018 Apr; 81(4):647-658. PubMed ID: 29464354
[TBL] [Abstract][Full Text] [Related]
18. Deep sequencing shows that oocytes are not prone to accumulate mtDNA heteroplasmic mutations during ovarian ageing.
Boucret L; Bris C; Seegers V; Goudenège D; Desquiret-Dumas V; Domin-Bernhard M; Ferré-L'Hotellier V; Bouet PE; Descamps P; Reynier P; Procaccio V; May-Panloup P
Hum Reprod; 2017 Oct; 32(10):2101-2109. PubMed ID: 28938736
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection.
Ziada AS; Lu MY; Ignas-Menzies J; Paintsil E; Li M; Ogbuagu O; Saberi S; Hsieh AYY; Sattha B; Harrigan PR; Kalloger S; Côté HCF;
Aging Cell; 2019 Dec; 18(6):e13018. PubMed ID: 31407474
[TBL] [Abstract][Full Text] [Related]
20. High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.
Guo W; He X; Ni J; Ma L; Cheng X; Wang C; Chen X; Wang Y
Front Oncol; 2021; 11():761960. PubMed ID: 34888242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
